Payment overview · 2025
General Payments
$275.46
14 reported records · 9 companies
Healthcare provider profile · identity verified
James G Staggs, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · COOKEVILLE, TN · NPI 1821107574
Verified facts
What the public records show
CMS Open Payments records show James G Staggs, D.O. received $275.46 in general payments during 2025 across 14 reported records.
GlaxoSmithKline, LLC. accounted for 20.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $57.40 | 20.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.44 | 20.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.07 | 14.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.91 | 9.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $25.15 | 9.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.00 | 7.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.24 | 6.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.89 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.36 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $275.46 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $57.40 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $40.07 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.95 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.91 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $25.15 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
102 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
134 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 511 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 501 | 124 |
| Clonazepam | Clonazepam | 351 | 62 |
| Losartan Potassium | Losartan Potassium | 327 | 101 |
| Pantoprazole Sodium | Pantoprazole Sodium | 324 | 98 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 90 |
| Lisinopril | Lisinopril | 270 | 77 |
| Gabapentin | Gabapentin | 268 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 214 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 66 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 206 | 61 |
| Glimepiride | Glimepiride | 196 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 58 |
| Metformin Hcl | Metformin Hcl | 180 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 179 | 55 |
| Omeprazole | Omeprazole | 172 | 50 |
| Sertraline Hcl | Sertraline Hcl | 164 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 163 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 44 |
| Potassium Chloride | Potassium Chloride | 156 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 148 | 44 |
| Meloxicam | Meloxicam | 148 | 44 |
| Eliquis | Apixaban | 134 | 31 |
| Furosemide | Furosemide | 132 | 46 |
| Famotidine | Famotidine | 123 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 110 | 17 |
| Allopurinol | Allopurinol | 107 | 33 |
| Mounjaro | Tirzepatide | 102 | 17 |
| Trazodone Hcl | Trazodone Hcl | 101 | 28 |
| Metformin Hcl Er | Metformin Hcl | 96 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 24 |
| Cefdinir | Cefdinir | 89 | 71 |
| Azithromycin | Azithromycin | 86 | 66 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 84 | 21 |
| Tramadol Hcl | Tramadol Hcl | 74 | 13 |
| Alendronate Sodium | Alendronate Sodium | 72 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 71 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 65 | 50 |
| Simvastatin | Simvastatin | 64 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 63 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 17 |
| Alprazolam | Alprazolam | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 13 |
| Atenolol | Atenolol | 55 | 16 |
| Montelukast Sodium | Montelukast Sodium | 55 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 22 |
| Farxiga | Dapagliflozin Propanediol | 50 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 15 |
| Ozempic | Semaglutide | 50 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 47 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 47 | 32 |
| Spironolactone | Spironolactone | 47 | 17 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 32 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 18 |
| Cephalexin | Cephalexin | 39 | 26 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 29 |
| Jardiance | Empagliflozin | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | 12 |
| Donepezil Hcl | Donepezil Hcl | 34 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 12 |
| Diazepam | Diazepam | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 26 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 30 | 14 |
| Estradiol | Estradiol | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | 12 |
| Metolazone | Metolazone | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Diclofenac Potassium | Diclofenac Potassium | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 16 |
| Valsartan | Valsartan | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $275.46 · 14 records | GlaxoSmithKline, LLC. | Auvelity, Cologuard Collection Kit, Ozempic, REXULTI, Rybelsus, SHINGRIX, VOQUEZNA, Veozah, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error